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Abstract:  
 
Resveratrol is a polyphenol antioxidant found in red wine known to have anti-aging, anti-cancer, 
and anti-obesity effects in both humans and animals.  Resveratrol's primary biological action is 
as an antioxidant, causing a reduction in reactive oxygen species (ROS).  ROS are produced as 
byproducts of normal metabolic functions, but become abnormally elevated in individuals who 
consume a high fat diet (HFD) or who have metabolic conditions like Type II Diabetes Mellitus 
(T2DM); in these circumstances, abnormal elevation in ROS leads to cellular damage and cell 
death.  Another common effect of a diet high in fat and calories is cognitive impairment: 
specifically, impaired memory.  Here, we tested the hypothesis that resveratrol might attenuate 
memory impairment caused by the ingestion of a high fat diet.  Animals on either a control 
(chow) diet or high fat diet (60% kcal fat) were treated with resveratrol (or vehicle) once weekly 
for 20 weeks.  Although no metabolic effects of the resveratrol treatment were seen, HFD 
animals treated with resveratrol performed significantly better in behavioral tasks, indicating a 
possible role of resveratrol as a therapeutic intervention to improve memory in individuals with 
metabolic dysregulation.  Additionally, healthy rats treated with resveratrol demonstrated a 
higher level of anxiety than their matched controls. Behavioral and metabolic measures were 
complemented by post-mortem measurement of molecular markers linked to memory formation, 
insulin signaling, and the cellular response to oxidative stress, intended to help elucidate 
neuroprotective mechanisms of resveratrol. Ultimately, this study indicates a possible role for 
resveratrol in preventative care for individuals prone to metabolic disease and related cognitive 
dysfunction.  
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Introduction: 
Obesity continues to increase in prevalence. It currently ranks third in leading causes of 
preventable deaths in the US, behind smoking and high blood pressure, respectively (Danaei et 
al., 2009). Obesity may arise from a variety of lifestyle factors, including inactivity, poor dietary 
habits, and stress; many individuals who are obese consume a diet high in saturated fat, simple 
sugars, and salt. If left unchecked, obesity can lead to inflammation and oxidative stress that may 
compromise an already unstable system. In particular, a diet rich in fat causes significantly 
increased production of reactive oxygen species (ROS) through excess lipid peroxidation and 
altered oxygen metabolism (Fernández-Sánchez, 2011). These ROS can lead to damage and may 
contribute to the development of insulin resistance, type II diabetes, cancer, and heart disease.  
Besides various physiological health risks, ingesting a high fat diet (HFD) also results in 
severe cognitive impairment, specifically in spatial memory tasks governed by the hippocampus 
(Kanoski & Davidson, 2011).  The hippocampus is extremely sensitive to metabolic changes and 
ROS, making it vulnerable to the effects of systemic obesity (Winocur & Greenwood, 2005). 
Besides changing diet and increasing daily physical activity, treatments for obesity may need to 
focus on reducing ROS in order to reduce the amount of damage, cognitive impairment, and risk 
of subsequent disease states.  
Resveratrol (3,4,5-trihydroxy-trans-stilbene) is a polyphenol antioxidant found in red 
wine that has potent effects on many different body systems. It has been proposed as a possible 
treatment for cancer, cardiovascular disease (Lin & Tsai, 1999), and ischemic injury due to 
stroke (Simão et al., 2012).  It has also been thrust into the media and clinical spotlight because 
of its apparent anti-aging and anti-angiogenic effects (Kasiotis, Pratsinis, Kletsas, & 
Haroutounian, 2013). In addition to a role in regulation of vascular supply, resveratrol is also of 
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interest as a potential therapeutic intervention for patients with metabolic diseases that may cause 
abnormally elevated oxidative stress, such as obesity.  In these patients, the potential role of 
resveratrol would be to reduce oxidative stress, which may be especially effective in obese, aged 
individuals. 
Resveratrol is able to ameliorate several causes of metabolic stress and dysfunction, but 
the exact molecular mechanisms behind its beneficial effects remain unknown. Specifically, 
resveratrol has been shown to protect against diet-induced obesity and systemic insulin 
resistance, improving both glycemic control through the AMPK pathway (Do et al., 2012) and 
insulin sensitivity by reducing oxidative stress and improving Akt signaling (Bransyó et al., 
2011).  It has also been shown to induce both the deacetylation and total expression of PGC-1α, a 
transcription factor involved in the regulation of gluconeogenesis and cellular metabolism, 
through activation of SIRT1 (Lagouge et al., 2006). All of these mechanisms may contribute to 
the renormalization of metabolism in obese individuals and reduction of overall oxidative stress. 
In addition to regulation of glucose metabolism, resveratrol has been shown to improve 
memory and ameliorate cognitive deficits that accompany metabolic and neurodegenerative 
disorders. Resveratrol improved word memory and reduced body fat in overweight humans 
(Witte et al., 2014). Additionally and more specifically, resveratrol was found to modulate 
molecules that participate in learning and memory and long-term potentiation (LTP): Zhao et al. 
showed that resveratrol treatment improved learning and memory formation and LTP induction 
in the hippocampi of mice via pathways involving reduced micro-RNA levels and increased 
CREB expression as well as brain-derived neurotrophic factor synthesis (Zhao et al., 2013). In 
hippocampal slices, evidence suggests that resveratrol may play a role in reducing glutamatergic 
excitotoxicity induced by overactivation and overexpression of NMDA and AMPA receptors 
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(Quincozes-Santos, 2014), which can occur in metabolic disorders including type 2 diabetes 
mellitus (Trudeau, Gagnon, & Massicotte, 2004) and neurodegenerative disorders such as 
Alzheimer’s disease (Felice, 2013). 
 Thus, several studies support a therapeutic potential for resveratrol to ameliorate 
cognitive deficits due to metabolic disorders. While these studies provide promising results, 
many of them have been conducted in vitro or in isolated animal models and the exact 
mechanisms by which resveratrol acts remain unknown. Additionally, many previous studies 
have examined the effects of resveratrol on molecular cascades in the periphery, such as 
reducing IGF-1 levels and corresponding insulin signaling in the liver (Baur et al., 2006) or 
increasing oxidative capacity and fatty acid oxidation by upregulating the transcription of related 
genes MCAD and UCP-3 in muscle (Lagouge et al., 2006). These studies fail to investigate 
specific mechanisms in the brain. 
By administering a high fat diet in conjunction with weekly injections of resveratrol, this 
project aimed to identify the exact molecular effects of resveratrol in the brain, specifically in the 
hippocampus. It was hypothesized that resveratrol treatment would ameliorate both the cognitive 
and metabolic deficits associated with a high fat diet. At the end of a twenty-week period, rats 
underwent a battery of cognitive tasks to assess the effects of resveratrol administration on 
specific cognitive regions in the brain. By comparing performance on behavioral tasks to levels 
of hippocampal receptors, transporters, and signal transducers, this project ultimately aimed to 
determine the mechanisms by which resveratrol acts both in the periphery and the brain.  
 
 
 
 
!9 
Materials and Methods: 
Animals 
All procedures were approved by the Institutional Animal Care and Use Committee at the 
University at Albany.  Forty Sprague-Dawley rats (Charles River, Wilmington, MA) were 
purchased at six weeks of age and doubly housed on a 12-hour light/dark schedule (lights on at 
7:00am).  After one week of acclimation, rats were randomly selected to receive regular Purina 
Chow diet (control; 3.35 kcal/g) or a diet consisting of 60% kcal from fat (D12492, Research 
diets, Inc.) (high fat diet; 5.24 kcal/g) and given ad libitum access to food and water.  Rats were 
maintained on their respective diets for 21 weeks until euthanasia by decapitation.    
Resveratrol Administration 
 Rats were pseudorandomly assigned to receive weekly injections of resveratrol or 
vehicle, creating four groups of animals in a 2x2 diet x treatment factorial design. Rats assigned 
to the resveratrol groups were injected at a dose of 20mg/kg. Injections continued once weekly 
for 20 weeks. Animals were handled immediately prior to injections and also at an additional 
time point during each week to ensure the animals were comfortable in the presence of the 
experimenters. 
Food Weights 
 Food weights were measured biweekly to monitor food intake. The food in each cage was 
replenished and the total weight of the food and the metal food dispenser was determined. After 
24 hours, food was removed from the cages and weighed again and the difference between the 
two measurements was calculated, indicating the amount of food ingested by both animals over 
the 24-hour period since rats were doubly housed throughout the duration of the project. Caloric 
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intake per cage was also monitored throughout the project. No data were collected on the feeding 
activity of individual animals.  
Behavioral Testing 
 The testing apparatus was thoroughly cleaned with 70% EtOH at the beginning and in 
between each animal and allowed time to dry. Behavioral testing occurred over the course of five 
days. At the end of each testing trial, animals were returned to their home cage.  
Day 1: Open Field 
 Animals were tested on the open field task as a measure of anxiety. Methods were 
adapted from Rogers et al. (1999).  The open field appraratus consists of an open field arena (76 
x 57 x 35 cm) divided into 16 squares with 12 on the periphery and 4 in the middle. Behavioral 
data were collected by an observer blind to the condition of experimental animals. Each rat was 
placed in the apparatus for 5 minutes and allowed to explore the apparatus freely.  Time spent in 
the center zone was measured and used as an indicator of anxiety, with less time spent in the 
center zone indicative of higher levels of anxiety.  
Day 1 and 2:Novel Object Recognition 
 Memory was tested with a novel object recognition task. Methods were adapted 
(Antunes, & Biala, 2012) and subjects were placed in the open field arena in the presence of two 
identical objects. Each rat was placed in the apparatus for 5 minutes and allowed to explore the 
apparatus and the objects for training. Time spent with both objects was measured during testing 
to ensure no preference between right or left identical objects. Followed by a 24-hour inter-trial 
interval, one object was replaced with one of a different shape, color, and texture and again rats 
were allowed to explore for 5 minutes. Time spent with each object was also measured during 
testing to compare time spent with the novel object with the time spent with the old object. A 
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larger percentage of time spent with the novel object during the testing period was interpreted as 
superior memory. All objects were sanitized with 70% EtOH between each animal.  
Day 3: Spontaneous Alternation 
 Spatial working memory was quantified by the use of the spontaneous alternation task. 
Methods were adapted from McNay et al., 2010. A 4-arm plus-maze was used. Animals were 
placed into the center of the maze always facing the same arm and allowed to explore freely for 
20 minutes before being removed and returned to their holding chamber.  The order of arm 
entries was recorded for later analysis. Alternation is defined as entry into all four arms within a 
five-arm entry period. 
Day 4 and 5: Conditioned Contextual Fear (CCF) 
Finally, hippocampally-dependent conditioned contextual fear was measured. Methods 
were adapted (Johansen, Cain, Ostroff, & LeDoux, 2011) and initially, rats were placed in a 
chamber with distinct spatial cues.  Following a 30-second habituation period, a tone sounded 
(5kHz) for 10 seconds and was followed immediately by five seconds of 0.8mA footshock.  This 
was repeated three times with one-minute inter-trial intervals.  Rats were returned to their 
homecage until testing 24 hours later when they were returned to the same context for three 
minutes, with the amount of time spent freezing recorded.  More time spent freezing is 
interpreted as better memory of the fearful context.  
Glucose Tolerance Test and Insulin Tolerance Test 
Blood glucose was measured every two weeks. Animals were fasted for one hour prior to 
testing.  Blood was obtained by tail-prick and measured using a blood glucose meter (OneTouch 
Ultra Mini Monitor). A glucose tolerance test was performed on each animal one week before 
behavioral testing. Animals were fasted for one hour and then administered an intra-peritoneal 
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(I.P.) injection of 1g/kg body weight D-(+)-glucose (Sigma-Aldrich, G8270), dissolved at 
concentration of 0.5g/mL in dH2O . Blood glucose was measured using a blood glucose meter at 
0 minutes (baseline, prior to glucose injection), 30 minutes after injection, 60 minutes after 
injection, and 120 minutes after injection. 
 An insulin tolerance test was also performed on each animal one week before behavioral 
testing, 6 hours after the glucose tolerance test.  Initial blood glucose was measured and human 
insulin was immediately injected at a dose of 6U/kg. Blood glucose was measured at 0 minutes 
(baseline, prior to insulin injection), 30, 60, 120, and 180 minutes after injection. If at any point a 
subject’s blood glucose dipped below 30mg/dl, their individual test was terminated and they 
were treated with an appropriate injection of glucose solution.  
Tissue, Trunk Blood, and Epididymal Fat Pad Collection 
The day following completion of behavioral testing, animals were killed by decapitation 
following anesthesia by isoflurane. Several brain regions were collected, including the pituitary 
gland, hypothalamus, sections of the prefrontal cortex, and the hippocampus. Each side of the 
dorsal hippocampus was dissected out and immediately processed for western blotting. Samples 
dissected from the periphery included fat, leg muscle, and samples from the stomach wall, liver, 
pancreas, and adrenal glands. All tissue samples were frozen on dry ice immediately after 
collection. Trunk blood was also collected, spun down at 2500 rpm for 10 minutes, and the 
serum fraction was collected for analysis. Epididymal fat pads were harvested from the carcass 
and weighed following trunk blood collection. 
Western Blotting 
Each side of the dorsal hippocampus was dissected out and immediately processed for 
western blotting. Both sides were homogenized together with 300uL of homogenization buffer 
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(BioVision) containing protease inhibitor (1:500) (BioVision) from which 30uL of homogenate 
was removed and combined with 200uL of RIPA buffer containing a protease and phosphatase 
inhibitor cocktail (1:200) (ThermoScientific). Initial homogenate was processed according to 
manufacturer’s instructions (BioVision) to isolate plasma membrane fractions from the total 
sample.  
All samples then underwent protein quantification using a BCA assay kit and 
manufacturer’s instructions were followed (Pierce Scientific). Using the data from the BCA 
assay, samples were mixed with 2x Laemmli sample buffer (BioRad) with 5% 2-
mercaptoethanol to achieve optimal sample amounts for total (20ug) and plasma membrane 
(5ug) samples. Total samples were heated in boiling water for 4 minutes prior to loading. Plasma 
membrane samples were not heated. All protein samples were loaded into pre-cast SDS-PAGE 
10% gels (BioRad) along with biotinylated ladder. Gels were run at 240V for 15 minutes and 
then 190V until the dye ran off the bottom of the gels (approximately 45 minutes). Once 
finished, the gels were transferred to PVDF membranes at 4oC for 1 hour. Membranes were 
removed and rinsed three times in TTBS and then blocked in 5% milk in TTBS.  
Primary antibodies were incubated overnight at 4oC for pAMPAR (Ser 845) GluR1 (Cell 
Signaling; 1:1000), AMPAR GluR3 (Cell Signaling; 1:1000), pAkt (Ser 473) (Cell Signaling; 
1:2000), Akt (Cell Signaling; 1:1000), pAMPK (Thr172) (Cell Signaling; 1:1000), AMPK (Cell 
Signaling; 1:1000), CREB (Cell Signaling; 1:750), GluT4 (Millipore; 1:1000), PGC-1α (Abcam; 
1:1000), NMDAR2B (Cell Signaling; 1:1000), or Nrf2 (Cell Signaling; 1:1000). After rinsing 
three times with TTBS, membranes were incubated in the species-appropriate biotinylated 
secondary antibodies at 1:10,000 in TTBS for one hour at 25oC. Once again, blots were rinsed 
three times with TTBS and incubated in tertiary HRP-streptavidin in 5% milk in TTBS for one 
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hour at 25oC. Membranes were rinsed three times with TTBS and twice with TBS, after which 
chemiluminescent (ThermoScientific) was applied and the blots were imaged using a BioRad 
ChemiDoc XRS imager.  Bands were analyzed using NIH free ImageJ software. 
Data Analysis  
All statistical analyses were performed with Graphpad Prism 6 software.  All results are 
depicted as mean + SEM and significance was set at a<0.05. Both two-way ANOVAs and two-
way repeated measures ANOVAs were used, with post hoc differences determined by specific 
planned comparisons using Bonferroni tests on the ANOVA analyses.  Data points two standard 
deviations or more away from the mean were excluded.  All abbreviations during data analysis 
are as follows: C/V—chow diet and vehicle injected; C/RSV—chow diet and resveratrol 
injected; HFD/V—high fat diet and vehicle injected; HFD/RSV—high fat diet and resveratrol 
injected. 
 
Results 
Resveratrol had no effect on body weight, food intake, or blood glucose 
Body weights were measured once weekly throughout the experiment. As seen in Fig. 1, 
resveratrol had no impact on body weight. Both groups sustained on the high fat diet weighed 
significantly more than the groups fed the regular chow diet (p<0.05), but there was no 
difference in weight between the two high fat diet groups or the two chow groups.  This is also 
shown in the post-mortem epididymal fat pad weights (Fig. 2). Resveratrol had no effect on fat 
pad weights, but diet had a significant effect (p<0.05) on fat composition.  
!15 
 
Figure 1: Body weights measured weekly over the course of 20 weeks. Diet had a significant 
main effect on weight gain, but resveratrol treatment had no effect. (*p<0.05) n=10 per group.   
 
Figure 2: Epididymal fat pad weights, measured at euthanasia. There was a main effect of diet on 
epididymal fat pad mass, while treatment had no effect. (*p<0.05) n=10 per group. 
 
Neither resveratrol nor diet had no effect on fasting blood glucose throughout the duration of the 
diet-treatment paradigm (Fig. 3).         
* 
* 
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Figure 3: Blood glucose levels measured biweekly. No significant effect of diet or treatment was 
found. n=10 per group. 
There was a significant effect of diet on food intake throughout the duration of the project: 
animals fed the high fat diet, regardless of treatment, ingested significantly less food than rats fed 
the control diet (Fig. 4a). However, there was no effect of diet or treatment on total caloric intake 
(Fig. 4b).  
a.         b.  
 
Figure 4: a. Food intake per cage measured biweekly. Those fed the control chow diet ate 
significantly more food than subjects fed the high fat diet. (*p<0.05) n=10 per group. 
b. Caloric intake per cage. No significant effects of diet or treatment were found. n=10 per group. 
 
* 
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Additionally, the glucose tolerance test (Fig. 5a) and insulin tolerance tests (Fig. 5b) did not 
reveal any significant patterns or differences in glucose metabolism due to diet or treatment.  
a.            b.  
    
Figure 5: a. Results of glucose tolerance test. Blood glucose was tested at t=0 (baseline), 30, 60, 
and 120 minutes post-injection. No significant effects were found. n=10 per group. 
b. Results of insulin tolerance test. Blood glucose was tested at t=0 (baseline), 30, 60, 120, and 
180 minutes post-injection. No significant effects were found. n=8-10 per group. 
Resveratrol and high fat diet modulate anxiety behavior 
Rats were tested in an open field paradigm to measure anxiety behavior. Animals in the chow-
resveratrol administration group spent significantly less time in the center zone than their 
matched controls. There was a significant interaction between the diet and treatment conditions 
for the open field task (Fig. 6).   
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Figure 6: Results of open field task. There was a significant interaction between diet and 
treatment in the open field task resulting in significantly decreased time spent in the center zone 
in the C/RSV and HFD/V groups. (*p<0.05) n=10 per group 
Resveratrol has no effect on spatial working memory 
Animals were tested on both the novel object recognition and spontaneous alternation task, both 
used to test hippocampal memory processes. Neither resveratrol nor diet had an effect on novel 
object recognition (Fig. 7a) or spontaneous alternation performance (Fig. 7b). 
a.           b.  
    
Figure 7: a. Results of novel object recognition task. No significant effects of diet or treatment 
were found. n=10 per group.  
* * 
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b. Results of spontaneous alternation task. No significant effects of diet or treatment were found. 
n=10 per group. 
Resveratrol improves contextual conditioned fear memory in rats fed a high-fat diet 
In the contextual conditioned fear task, animals that were maintained on the high-fat diet 
demonstrated decreased freezing behavior, suggesting memory impairment due to the high fat 
diet. However, when resveratrol was co-administered along with the high-fat diet, animals 
performed comparably to controls given vehicle. In the contextual conditioned fear task, 
resveratrol was able to ameliorate cognitive deficits initially caused by the high-fat diet (Fig. 8).  
! 
Figure 8: Results of conditioned contextual fear task. There was a significant interaction between 
diet and treatment in this task. (*p<0.05) n=10 per group 
Resveratrol and diet exert differential effects on molecular markers of memory and metabolism 
In order to investigate the effects of diet and treatment on molecular markers of memory 
and metabolism, western blotting of hippocampal homogenates was conducted with both total 
and plasma membrane fractions. Blots were probed for total (T) amounts of pAkt/Akt, 
pAMPAR/AMPAR, pAMPK/AMPK, CREB, GluT4, Nrf2, and PGC-1α and plasma membrane 
(PM) amounts of AMPAR, NMDAR, and GluT4. All protein measures are reported as percent 
control after being normalized to β-actin, unless otherwise specified.  
* * 
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 A significant effect of diet was seen in total levels of Akt (Fig. 9a), but not in its 
activated, phosphorylated form (Fig. 9b).  
a.           b. 
! !! ! 
Figure 9: a. Relative optic density of Akt:β-Actin. There was a significant main effect of diet on 
Akt levels. (*p<0.05) n=10 per group. 
b. Relative optic density of pAkt:Akt, both normalized to β-actin. A significant main effect of 
diet was also found for pAkt. (p<0.05) n=10 per group. 
No significant effects were seen in PGC-1α expression (Fig. 10) 
 
Figure 10: Relative optic density of PGC-1α:β-Actin. No significant effects of diet or treatment 
were observed with this target. n=10 per group. 
Significant effects were seen in both levels of phosphorylated AMPAR (Fig. 11b) and total 
AMPAR (Fig. 11c), but no effects were seen in levels of plasma membrane AMPAR (Fig 11a).  
* 
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a.         b.  
   
c.  
 
Figure 11: a. Relative optic density of AMPAR (PM): AMPAR (T), a measure of translocation to 
the plasma membrane and therefore active presence in the synapse. Both normalized to β-actin. 
No significant differences were seen between groups due to diet or treatment. n=10 per group 
b. Relative optic density of pAMPAR:AMPAR, both normalized to β-actin. A significant main 
effect of diet was present in the resveratrol-treated groups. (*p<0.05) n=10 per group 
c. Relative optic density of AMPAR(T):β-Actin.  A significant main effect of treatment was 
found in the chow-fed groups. (*p<0.05) n=10 per group 
There were no effects seen in either total levels of NMDAR (Fig. 12a) or amounts of NMDAR in 
the plasma membrane (Fig. 12b). 
 
 
* 
* 
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a.             b.  
  
Figure 12: a. Relative optic density of NMDAR (PM):NMDAR (T), both normalized to β-actin. 
No significant differences between groups were observed. n=10 per group 
b. Relative optic density of NMDAR (T):β-Actin. A significant main effect of treatment was 
found. (p<0.05) n=10 per group.  
No effects of diet or treatment were seen in the transcription factor CREB (Fig. 13).  
 
Figure 13: Relative optic density of CREB:β-Actin. No significant effects were found. n=10 per 
group 
Additionally, no significant effects were seen in the oxidative stress marker NrF2 (Fig. 14).  
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Figure 14: Relative optic density of NrF2:β-Actin. No significant effects were found. n=10 per 
group. 
Total levels of AMPK showed no response to treatment or diet (Fig. 15a). However, pAMPK 
demonstrated a robust interaction between the two variables, with pAMPK levels significantly 
heightened in the C/RSV and HFD/V groups, but lower in the C/V and HFD/RSV groups (Fig. 
15b).  
a.            b.  
!  !  
Figure 15: a. Relative optic density of AMPK:β-Actin. No significant effects were found. n=8 
per group. 
b. Relative optic density of pAMPK:AMPK, both normalized to β-Actin. A significant 
interaction was found between diet and treatment in this target. (*p<0.05) n=8 per group. 
 
* * 
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Total levels of GluT4 were subject to a significant interaction between diet and treatment (Fig. 
16a), but there were no significant differences between groups in the plasma membrane fractions 
(Fig. 16b), indicating that resveratrol or diet did not have an effect on the translocation and 
therefore greater usage of GluT4. 
a.           b.  
  
Figure 16: a. Relative optic density of total GluT4:β-Actin. A significant interaction was found 
between diet and treatment. (*p<0.05) n=10 per group 
b. Relative optic density of GluT4 (PM): GluT4 (T), both normalized to β-Actin. No significant 
results were found in this case. n=10 per group 
 
Discussion 
 Administration of resveratrol alongside a high-fat diet over the course of 20 weeks 
revealed interesting patterns in physiological responses and behavior. Unlike several studies that 
provide evidence for resveratrol’s role in reducing weight gain while ingesting a high-fat diet 
(Lagouge et al., 2006; Kim, Jin, Choi, & Park, 2011), we found no differences in weight between 
HFD-fed rats treated with resveratrol and those given vehicle. The significant differences in 
epididymal fat pad weight support the conclusion drawn from body weight measurements that 
weight gain on a HFD was due to increased obesity, but resveratrol administration had no effect 
* * 
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on weight gain or body fat content. Resveratrol also did not exert a metabolic effect on the blood 
glucose levels of high fat diet rats as compared to their controls.  
 While resveratrol did not cause any significant changes in body weight, fat content, or 
blood glucose, it did exert significant behavioral effects. Resveratrol administration to rats fed a 
chow diet caused a significant decrease in time spent in the center zone during the open field 
task, indicating a high level of anxiety as compared to its control. Additionally, HFD/V animals 
also showed significantly heightened anxiety in this task. In the resveratrol treated groups, diet 
had an effect on anxiety behavior, with the HFD/RSV animals demonstrating less anxiety 
behavior than their chow-diet counterparts. Resveratrol did not have an effect on the behavior of 
rats in the novel object recognition task or the spontaneous alternation task. This is surprising 
because resveratrol has demonstrated the ability to affect performance on these tasks using an 
identical dose (Anastácio, 2014).  
In the conditioned contextual fear task, resveratrol treatment of high fat diet rats 
ameliorated the deficit seen in HFD/V animals, and allowed the HFD/RSV cohort to perform at 
levels comparable to controls. Previously, the open field task revealed resveratrol’s role as a 
possible anxiety-inducing agent in the C/RSV group, which may have manifested itself in the 
improvement in performance in the HFD/RSV group in the conditioned contextual fear task. 
Future studies should address the exact mechanisms by which resveratrol moderates fear 
memory in the hippocampus and how it possibly can be modulated by a change in diet.  
These behavioral results, considering that resveratrol did not reduce weight gain in rats 
fed a HFD, supports the hypothesis that resveratrol alone is responsible for the improved 
performance of rats receiving the experimental treatment in the HFD condition. High fat diets are 
associated with hippocampal dysfunction and therefore poor performance on related behavioral 
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tasks (Kanoski & Davidson, 2011) and weight loss can attenuate this dysfunction (Miller et al., 
2013). It is clear that there is no significant difference in weight between the HFD/V and 
HFD/RSV groups, supporting the claim that resveratrol treatment was responsible for the 
improved performance of the HFD/RSV group on the CCF task.  
The preliminary molecular results show some expected and unexpected patterns. Akt 
levels were decreased in the high fat diet groups, which may be indicative of overall impaired 
insulin signaling in both groups. No other group demonstrated a deficit in Akt levels and there 
was no effect of diet or treatment on pAkt levels. There was no indication that levels of oxidative 
stress were high in either of the high fat diet groups, contrary to original thought. Resveratrol or 
diet also did not exert an effect on CREB, a surprising result since this has been demonstrated 
before, albeit in a slightly different context (Zhao et al., 2013).  
Resveratrol and diet both had differing effects on AMPAR activity and overall 
expression. Phosphorylated AMPAR levels were significantly decreased in HFD/RSV rats 
compared to C/RSV rats, indicating a main effect of diet on pAMPAR levels. AMPAR is 
phosphorylated by PKA at serine 845 in its GluR1 subunit in order to increase its open 
probability, and therefore become more active in the synapse (Banke, Bowie, Lee, Huganir, 
Schousboe, & Traynelis, 2000). While pAMPAR levels were decreased due to high fat diet in the 
resveratrol treated groups, overall AMPAR levels were significantly lower in C/RSV animals as 
compared to their vehicle-treated controls, indicating a main effect of treatment. It is not clear if 
this relationship has meaning in the context of the behavioral results, but future studies could 
possibly elucidate this relationship and how it may result in the modulation of behavior.  
Resveratrol increased pAMPK levels in the C/RSV group while diet seems to be the 
primary cause of pAMPK activation in the HFD/V group. There was a strong interaction 
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between diet and treatment for pAMPK. Resveratrol is a known AMPK activator (Patel, Gupta, 
& Dey, 2011) and additionally is upregulated in a high-fat, high fuel state inducing glucose 
usage and therefore energy production (Pellatt, Rice, & Mason 2011). The interesting effect in 
this case is among the HFD/RSV group where, despite the fact that they are being treated with 
resveratrol and being fed a high fat diet and should, according to the other groups, demonstrate 
the highest level of pAMPK, their levels are comparable to controls. More research must be done 
investigating the relationship between the diet and treatment and how it relates to AMPK 
activation, especially in the HFD/RSV condition.  
Total GluT4 levels also demonstrated an interaction between diet and treatment. Total 
GluT4 levels were decreased in both the C/RSV and HFD/V groups as compared to C/V, 
indicating that both resveratrol treatment and diet may have an effect on total GluT4 levels. 
However, the amount of GluT4 found in the plasma membrane remained unaffected by treatment 
or diet.  
These behavioral and molecular effects may provide support for an inverted-U dose 
effect of resveratrol in regards to metabolism. As indicated by the open field task, resveratrol 
resulted in high levels of anxiety behavior in the C/RSV group, but caused no issues in the 
HFD/RSV group. In the the CCF task, however, resveratrol supplementation aided the 
HFD/RSV group in performing the task at comparable levels to controls and nonsignificantly 
decreased performance in the C/RSV group. These results support a metabolically-dependent 
model for resveratrol’s effects, where it is helpful when administered alongside a high fat diet 
but detrimental when given with a healthy diet. This hypothesis is further supported by the 
molecular results of pAMPK levels, which are significantly heightened in the C/RSV and 
HFD/V groups, but at lower levels in the C/V and HFD/RSV groups. It has been postulated that 
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overactivation of the AMPK pathway may lead to impairment of normal memory functions 
(Dash, Orsi, & Moore, 2006), which may help explain why resveratrol treatment of chow-fed 
rats seemed to be detrimental to their performance. Future studies should aim to parse out the 
exact effects of resveratrol on anxiety and AMPK to explain the behavioral and molecular effects 
seen in these two tasks.  
The overall findings presented in this study are significant but require further 
investigation in all areas before definitive conclusions can be drawn. An aspect of its lack of 
strength is the failure of the molecular data to align with the observed behavioral effects. 
Previous studies have demonstrated resveratrol’s specific effects on AMPAR/NMDAR activity 
and expression (Quincozes-Santos, 2014), AMPK activation (Do et al., 2012), and the 
transcriptional activity of PGC-1α (Lagouge et al., 2006). While some of these effects are seen in 
the molecular data, not all effects are present or resemble previous studies.  The few studies that 
have addressed the behavioral component of resveratrol’s effects have shown similar results. For 
example, using rats with streptozotocin-induced diabetes, Shmatz et al. demonstrated that a 
20mg/kg dose of resveratrol could ameliorate cognitive deficits associated with diabetes (Shmatz 
et al., 2009).  
Some of the major differences between this study and those previously conducted are the 
dosage, method of delivery, and frequency of delivery of resveratrol. In the literature, the dose of 
resveratrol given to subjects varies greatly from 1mg/kg (Carbo et al., 1999) to 400mg/kg 
(Lagouge et al., 2006). It is possible that the dose administered in this study was lower than 
optimum.  
Additionally, the route of administration differs across all studies. Some groups mix 
resveratrol into the food (Baur et al., 2006), which normally corresponds to higher doses of 
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resveratrol to account for loss during digestion. Other methods include subcutaneous Alzet 
pumps (Robb et al., 2008), dissolving in water (Rivera, Morón, Zarzuelo, & Galisteo, 2009), 
intraperitoneal injections (Simão et al., 2012), or microinjection directly into the brain region of 
interest (Zhao et al., 2013). Each of these delivery systems confers a specific delivery frequency 
as well. If resveratrol is dissolved into the animal’s water or mixed into their food and they are 
given ad libitum access, then their dosage will be more or less continuous. The same logic holds 
for the Alzet pump method. Alternatively, microinjection can only be accomplished in very 
small doses over shorter periods of time. Injections can be given anywhere from multiple times 
per day to one single dose, which adds yet another level of variability to this issue.  
Lastly, many of these effective doses are not feasible for humans. Due to a lack of human 
trials, it is not clear if resveratrol is safe if administered at the same doses. It may take up to two 
grams of resveratrol each day to mimic the dose and frequency of treatment of some of these 
studies. It is also clear that resveratrol has the capacity to act as a non-steroidal anti-
inflammatory drug and taking it alongside other NSAIDs or cancer therapeutics can increase the 
risk for bleeding and other complications (Baek, Wilson, & Eling, 2002). Despite promising 
evidence from animal models, it is too soon to tell the possible efficacy of human resveratrol 
supplementation.  
While this behavioral and physiological data are promising, further investigation must be 
completed to elucidate the exact mechanisms of the behavioral effects resveratrol. Resveratrol is 
a promising possible therapeutic that is currently undergoing human studies in the fields of 
cancer, stroke, diabetes, and neurodegenerative diseases. If the behavioral and molecular effects 
of resveratrol treatment were decoded, then physicians might be more confident in its life-
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preserving qualities and might be more willing to prescribe it before resorting to complicated and 
often harmful pharmaceutical treatments.  
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